Reviewing the Latest Treatment Advancements in ALL

May 6, 2019
Elias Jabbour, MD

Elias Jabbour, MD, discusses the latest advancements in the treatment landscape for acute lymphocytic leukemia that are moving the paradigm away from chemotherapy.

Elias Jabbour, MD, professor of medicine at The University of Texas MD Anderson Cancer Center, discusses the latest advancements in the treatment landscape for acute lymphocytic leukemia (ALL) that are moving the paradigm away from chemotherapy.

There has been a lot of evolution in this field, including the development of tyrosine kinase inhibitors (TKIs), monoclonal antibodies, bispecific T-cell engager (BiTE) antibodies, and CAR T cells, Jabbour says. For patients with Philadelphia chromosome-positive ALL, TKIs in combination with chemotherapy have shown great benefit in improving survival. Today, survival at 5 years is approaching 70%, Jabbour says.